Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Onshore Yuan Breaks 6.9 Against U.S. Dollar as Trade War Intensifies
China Unicom Steps Up Mixed-Ownership Reform in Yunnan
Regulator Finds Kangmei Pharma Fabricated Financial Reports
LATEST
E-Commerce Newcomer Pinduoduo Beats Market Expectations in First Quarter
Ni Hao, Alexa: China Passes U.S. to Become World’s Largest Smart-Speaker Market
Central Bank to Unify Benchmark, Market-Based Lending Rates
JP Morgan Banker Offered Job to Kerry Logistics Scion in Bribery Case
Swiss Drone Makers Eye Chinese Market
Solar Energy Firm Hanergy to Delist From Hong Kong
Beingmate Gets Off Delisting Watchlist — But Has It Really Turned a Corner?
In Depth: Xiangshui Chemical Factory’s Recipe for Disaster
China Unicom Steps Up Mixed-Ownership Reform in Yunnan
Regulator Finds Kangmei Pharma Fabricated Financial Reports
Onshore Yuan Breaks 6.9 Against U.S. Dollar as Trade War Intensifies
Stricter Vehicle Emission Standards May Spell Further Bad News for Hobbled Industry
China Gives Tech SOEs Deadline for Improving Employee Incentives
Home Prices Rise in Major Chinese Cities
Taiwan Lawmakers Approve Same-Sex Marriage Bill
Former JP Morgan Banker Charged With Bribery in Hong Kong
Legendary Architect I.M. Pei Dies at 102
Clock Ticks Down to Starbucks Challenger Luckin’s New York Trading Debut
China Regulates Deposit Abuse in Sharing Economy
Don’t Overestimate Swine Fever Impact on 2019 Inflation, NDRC Says
China’s Rising Vaccine Star Struggles to Reassure Investors After Halting Production

By Zhao Runhua, Wang Luyao and Liu Denghui / Apr 09, 2019 03:42 PM / Business & Tech

Photo: VCG

Photo: VCG

A rising star in China’s biotech industry is now raising concerns about the country’s ability to produce its own vaccines.

Chongqing Zhifei Biological has halted the production of its own meningitis vaccine AC-Hib, the company announced last week – a move that may keep investors at bay.

The company’s previous license to produce the vaccine expired April 1, and it has yet to receive a new one, despite having applied for renewal in November, according to the company’s official statement.

Regulations stipulate that a company needs to apply for a license once every five years in order to produce a vaccine, and Zhifei’s last approval for AC-Hib came in 2014. It is not clear if its license’s renewal this time around has been postponed or rejected.

Zhifei still sells HPV vaccines developed by global giant MSD, with which it shares revenues for China sales, but the AC-Hib has been a major revenue channel for the company.

Industry watchers say Zhifei’s case signals the increasingly tight supervision of vaccine production after scandals caused nationwide concern. Last year, Changsheng Bio-Technology caused outrage after it was found to have produced and sold roughly 500,000 substandard vaccines for babies.

Zhifei booked a total 2018 revenue of 5.2 billion yuan ($744 million), up 289.4% year-on-year. And the company’s net profit climbed 235.8% to 1.5 billion yuan for the same period.

But even strong overall performance may not reassure investors – an 8 billion yuan market value of the company's stock in Shenzhen Growth Enterprise Market evaporated in just one day after company’s statement. Since then, the company’s stock has dropped over 10%.

Related: 4 Things to Know About China’s Vaccine Scandal

 


Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.